SCHEMBL13080845

SCHEMBL13080845

BC1=CC(=O)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 6/20 0.50
IDO1 P14902 3/20 0.50
MAOA P21397 3/20 0.50
MAOB P27338 2/20 0.50
SNCA P37840 2/20 0.50
AKT1 P31749 1/20 0.50
MAP2K1 Q02750 1/20 0.50
PIN1 Q13526 1/20 0.50
EHMT2 Q96KQ7 1/20 0.50
NSD1 Q96L73 1/20 0.50
EHMT1 Q9H9B1 1/20 0.50
CDC25A P30304 4/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
LMNA P02545 4/20 0.48
MAPT P10636 4/20 0.48
MAPK1 P28482 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 3/20 0.48
PLIN1 O60240 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13769114 0.85 CDC25B (0.56) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL8559293 0.73 BACE1 (0.45) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL9286666 0.72 BACE1 (0.60) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL1708066 0.72 BACE1 (0.60) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL9915565 0.68 MAPT (0.74) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL6345958 0.68 PTPRC (0.74) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL17861314 0.68 CDC25B (0.74) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL6555840 0.68 BACE1 (0.75) CDC25BIDO1MAOAMAOBSNCA
SCHEMBL11566065 0.68 IDO1 (0.50) CDC25BIDO1MAOAMAOBSNCA
Naphthoquinone SCHEMBL11359780 0.67 IDO1 (1.00) CDC25BIDO1MAOAMAOBSNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292292-A1 Treatment of Neurodegenerative Diseases Using Indatraline Analogs LINK MEDICINE CORPORATION (US) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292292-A1 Treatment of Neurodegenerative Diseases Using Indatraline Analogs HTT, SNCA, PARK7 CDC25B 4802/4885IDO1 13/4885MAOA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.